Visão geral da empresa
A clinical-stage biopharmaceutical enterprise, Tvardi Therapeutics, Inc. focuses on the creation of novel oral small molecule therapies designed to target signal transducer and activator of transcription 3 (STAT3) for the treatment of inflammatory and proliferative diseases. The company operates within the Healthcare sector, specifically in the Biotechnology industry, a classification that implies a high degree of scientific research intensity and reliance on regulatory approval processes before commercialization. Tvardi Therapeutics holds a market capitalization of $28.61M, employs 12 staff members, and currently reports no annual revenue figures as its price-to-sales metric is not applicable. The combination of a market cap under $30 million and the absence of reported revenue indicates that the company is in an early developmental stage where capital is primarily allocated toward research and development rather than commercial sales generation.
Saúde financeira
The financial statements for Tvardi Therapeutics show a Net Income (TTM) of $-18,214,000, an EBITDA of $-26,653,000, and Revenue (TTM) listed as N/A. The significant negative gap between the non-existent revenue and the substantial net losses reveals a cost structure dominated by operational expenses related to drug discovery, clinical trial initiation, and general corporate administration rather than cost of goods sold. The company reports a Free Cash Flow of $-15,216,500, which indicates that current cash reserves are being consumed to fund operations and development activities without generating positive operating cash flow. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the typical pre-revenue status where costs are incurred without corresponding sales to generate a margin. Regarding leverage, the company holds $30.81M in Cash against $201,000 in Debt, resulting in a Debt to Equity ratio of 0.96, suggesting a balance sheet that is heavily weighted toward cash assets with minimal debt obligations relative to equity. The Current Ratio stands at 2.86, indicating that the company possesses sufficient liquid assets to cover its short-term liabilities with a comfortable buffer. Furthermore, the Return on Equity is -237.8% and the Return on Assets is -49.7%, metrics that reveal that management has not yet generated positive returns on shareholder capital or asset base, a characteristic common for biotechnology firms in the clinical-stage phase.
Avaliação de valorização
Valuation metrics for Tvardi Therapeutics present a mixed picture of traditional profitability measures versus market pricing, with a Trailing P/E Ratio (TTM) listed as N/A due to the lack of earnings and a Forward P/E of -1.17. The negative forward P/E implies that the market prices the stock based on expected losses or that the denominator in the earnings calculation is negative, complicating the standard interpretation of earnings trajectory. The Price to Book ratio is 1.37, indicating that the market values the company at a 37% premium over its tangible book value, which may reflect the potential value of its intellectual property pipeline despite current financial losses. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of 0.07, suggesting that the enterprise value is very close to its earnings before interest, taxes, depreciation, and amortization, though the low figure is skewed by the negative earnings profile. The stock has traded within a 52-week range defined by a high of $43.65 and a low of $2.81, placing the current valuation context within this wide band of volatility. The Beta is listed as N/A, meaning there is no calculated measure of price volatility relative to the broader market provided in the available data to assess systematic risk.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue as neither positive growth figures nor negative declines are quantified in the available data. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all available earnings to reinvest into its research and development pipeline rather than distributing income to shareholders. This non-dividend status is typical for biotechnology firms that prioritize funding clinical trials and expanding their therapeutic portfolio over providing immediate income returns to investors. Consequently, the overall growth and income profile is characterized by a reliance on capital appreciation potential derived from future commercialization of STAT3-targeted therapies rather than current cash flow generation or dividend income.